UA41305C2 - Cпосіб лікування незлоякісної гіперплазії простати та фармацевтична композиція для його здійснення - Google Patents
Cпосіб лікування незлоякісної гіперплазії простати та фармацевтична композиція для його здійсненняInfo
- Publication number
- UA41305C2 UA41305C2 UA94061635A UA94061635A UA41305C2 UA 41305 C2 UA41305 C2 UA 41305C2 UA 94061635 A UA94061635 A UA 94061635A UA 94061635 A UA94061635 A UA 94061635A UA 41305 C2 UA41305 C2 UA 41305C2
- Authority
- UA
- Ukraine
- Prior art keywords
- realization
- pharmaceutical composition
- benign prostate
- prostate hyperplasia
- treating benign
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Спосіб лікування незлоякісної гіперплазії простати включає застосування інгібітору 5 -редуктази. Призначають терапевтично ефективну кількість інгібітору 5.-редуктази у комбінації з -адренергичним блокатором рецептора.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67251191A | 1991-03-20 | 1991-03-20 | |
US84615392A | 1992-03-11 | 1992-03-11 | |
PCT/US1992/002258 WO1992016213A1 (en) | 1991-03-20 | 1992-03-19 | Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen |
Publications (1)
Publication Number | Publication Date |
---|---|
UA41305C2 true UA41305C2 (uk) | 2001-09-17 |
Family
ID=27100766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA94061635A UA41305C2 (uk) | 1991-03-20 | 1992-03-19 | Cпосіб лікування незлоякісної гіперплазії простати та фармацевтична композиція для його здійснення |
Country Status (18)
Country | Link |
---|---|
US (2) | US5753641A (uk) |
EP (1) | EP0576603A1 (uk) |
JP (1) | JPH06506227A (uk) |
AU (1) | AU666846B2 (uk) |
BG (1) | BG61798B1 (uk) |
CA (1) | CA2104793C (uk) |
CZ (1) | CZ292712B6 (uk) |
HU (1) | HUT66273A (uk) |
IE (1) | IE920879A1 (uk) |
IL (1) | IL101243A (uk) |
NO (1) | NO305635B1 (uk) |
NZ (1) | NZ241979A (uk) |
RO (1) | RO113613B1 (uk) |
RU (1) | RU2125879C1 (uk) |
SG (1) | SG80530A1 (uk) |
SK (1) | SK284381B6 (uk) |
UA (1) | UA41305C2 (uk) |
WO (1) | WO1992016213A1 (uk) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0547687A1 (en) * | 1991-12-18 | 1993-06-23 | Merck & Co. Inc. | 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones |
JPH07505398A (ja) * | 1992-04-02 | 1995-06-15 | スミスクライン・ビーチャム・コーポレイション | 良性前立腺肥大症の治療用組成物および方法 |
CA2147866A1 (en) * | 1992-11-04 | 1994-05-11 | Nancy M. Gray | Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis |
CA2158345A1 (en) * | 1993-03-15 | 1994-09-29 | Marvin L. Bayne | Cloned human alpha 1c adrenergic receptor |
TW408127B (en) * | 1993-09-17 | 2000-10-11 | Glaxo Inc | Androstenones |
TW369521B (en) * | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
US5525608A (en) * | 1994-04-20 | 1996-06-11 | Merck & Co., Inc. | 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors |
US5817818A (en) * | 1994-09-16 | 1998-10-06 | Glaxo Wellcome Inc. | Androstenones |
US5541322A (en) * | 1994-10-14 | 1996-07-30 | Glaxo Wellcome Inc. | Synthesis of 6-azaandrostenones |
US5952351A (en) * | 1995-02-23 | 1999-09-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6096763A (en) * | 1995-02-23 | 2000-08-01 | Merck & Co., Inc. | α1a adrenergic receptor antagonists |
GB9603457D0 (uk) * | 1996-02-19 | 1996-04-17 | Merck & Co Inc | |
US5670643A (en) * | 1995-03-16 | 1997-09-23 | Glaxo Wellcome Inc. | Method for preparing finasteride |
GB9506678D0 (en) * | 1995-03-31 | 1995-05-24 | Glaxo Inc | Substituted 6-azacholesten-3-ones |
US6001844A (en) * | 1995-09-15 | 1999-12-14 | Merck & Co., Inc. | 4-Azasteroids for treatment of hyperandrogenic conditions |
US6177430B1 (en) | 1997-03-27 | 2001-01-23 | Pfizer Inc | Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
US5922722A (en) * | 1996-11-12 | 1999-07-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
US6057350A (en) * | 1997-06-18 | 2000-05-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6143750A (en) * | 1997-06-18 | 2000-11-07 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6214832B1 (en) | 1997-06-18 | 2001-04-10 | Merck & Co., Inc. | Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists |
US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6376503B1 (en) | 1997-06-18 | 2002-04-23 | Merck & Co., Inc | Alpha 1a adrenergic receptor antagonists |
US5998427A (en) * | 1998-05-14 | 1999-12-07 | Glaxo Wellcome Inc. | Androstenones |
AU5234899A (en) | 1998-07-30 | 2000-02-21 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
AU1808400A (en) | 1998-10-29 | 2000-05-22 | Merck & Co., Inc. | Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists |
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
AU1345600A (en) | 1998-11-12 | 2000-06-05 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
US6423719B1 (en) | 1999-02-16 | 2002-07-23 | Upsher-Smith Laboratories, Inc. | Method for treating benign prostate hyperplasia |
US6313131B1 (en) | 1999-02-16 | 2001-11-06 | Upsher-Smith Laboratories, Inc. | Method of kidney treatment |
GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
US6200573B1 (en) | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
WO2003005889A2 (en) * | 2001-07-10 | 2003-01-23 | Ams Research Corporation | Surgical kit for treating prostate tissue |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
WO2003026568A2 (en) * | 2001-09-21 | 2003-04-03 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
CN1646135A (zh) * | 2002-04-24 | 2005-07-27 | 贝林格尔英格海姆法玛两合公司 | 治疗良性前列腺增生或长期预防急性尿潴留的药物组合 |
WO2004059036A2 (de) * | 2002-12-23 | 2004-07-15 | Basf Aktiengesellschaft | Hydrophob-hydrophile verbindungen zum behandeln von metallischen oberflächen |
EP1641535A4 (en) * | 2003-06-30 | 2008-05-14 | Merck & Co Inc | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS |
WO2005005606A2 (en) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
CN1816528A (zh) * | 2003-06-30 | 2006-08-09 | 麦克公司 | 作为雄激素受体调节剂的17-乙酰氨基-4-氮杂甾类衍生物 |
JP2007522087A (ja) * | 2003-06-30 | 2007-08-09 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体 |
EP2099375B1 (en) | 2007-01-02 | 2014-09-24 | AquaBeam LLC | Minimally invasive devices for the treatment of prostate diseases |
US9232959B2 (en) | 2007-01-02 | 2016-01-12 | Aquabeam, Llc | Multi fluid tissue resection methods and devices |
MX2007003949A (es) * | 2007-04-02 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos. |
US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
US20090076058A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched finasteride |
EP2259742B1 (en) | 2008-03-06 | 2020-01-01 | AquaBeam LLC | Tissue ablation and cautery with optical energy carried in fluid stream |
GR1006492B (el) * | 2008-05-29 | 2009-07-22 | Νικολαος Χρηστου Δημοφιλος | Συνεργατικη επαγωγη αποπτωσης προστατικου ιστου-προληψη καρκινου προστατου-νεα πρακτικη περιφερικου ανδρογονικου αποκλεισμου-κατασκευη συμπλοκου δισκιου |
US9848904B2 (en) | 2009-03-06 | 2017-12-26 | Procept Biorobotics Corporation | Tissue resection and treatment with shedding pulses |
WO2016004071A1 (en) | 2014-06-30 | 2016-01-07 | Procept Biorobotics Corporation | Fluid jet tissue resection and cold coagulation (aquablation) methods and apparatus |
JP2014510045A (ja) | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
BRPI1103204A2 (pt) * | 2011-06-03 | 2014-02-25 | Eurofarma Lab S A | Composição farmacêutica para o tratamento de hiperplasia prostática benigna |
EP3351196A1 (en) | 2012-02-29 | 2018-07-25 | Procept Biorobotics Corporation | Automated image-guided tissue resection and treatment |
EP2956070A4 (en) | 2013-02-14 | 2016-12-07 | Procept Biorobotics Corp | METHOD AND DEVICE FOR AQUABLATION AQUABEAM EYE SURGERY |
MX2016001032A (es) * | 2013-07-23 | 2017-10-31 | Allergan Inc | Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. |
CA2919198A1 (en) | 2013-07-23 | 2015-01-29 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist |
CN105764436B (zh) | 2013-09-06 | 2019-04-26 | 普罗赛普特生物机器人公司 | 利用致脱脉冲的用于消融组织的装置 |
CN107072591B (zh) | 2014-09-05 | 2021-10-26 | 普罗赛普特生物机器人公司 | 与靶器官图像的治疗映射结合的医师控制的组织切除 |
CN104277089A (zh) * | 2014-09-30 | 2015-01-14 | 湖南科瑞生物科技有限公司 | 一种雄甾-17β-羧酸的制备方法 |
KR20240010751A (ko) | 2014-11-20 | 2024-01-24 | 세레니티 파마슈티컬즈 엘엘씨 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
KR102680792B1 (ko) * | 2018-12-06 | 2024-07-03 | 경희대학교 산학협력단 | 신코닌을 유효성분으로 포함하는 전립선비대증의 예방 또는 치료용 조성물 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
GB1156973A (en) * | 1965-07-06 | 1969-07-02 | Quinazoline Derivatives | |
US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
US3980650A (en) * | 1972-05-05 | 1976-09-14 | N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia | 4-Amino-pyrimidine derivatives |
JPS4966691A (uk) * | 1972-10-30 | 1974-06-27 | ||
US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
GB2007656B (en) * | 1977-11-05 | 1982-05-19 | Pfizer Ltd | Therapeutic agents |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
AU527030B2 (en) * | 1978-04-13 | 1983-02-10 | Merck & Co., Inc. | 4-aza-17-substituted-5a-androstan-3-ones |
US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
US4220775A (en) * | 1979-03-15 | 1980-09-02 | Merck & Co., Inc. | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors |
EP0314199B1 (en) * | 1984-02-27 | 1991-09-18 | Merck & Co. Inc. | 17 beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors |
NZ211145A (en) * | 1984-02-27 | 1988-10-28 | Merck & Co Inc | 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions |
US4760071A (en) * | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
US4859681A (en) * | 1984-02-27 | 1989-08-22 | Merck & Co., Inc. | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors |
CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4888366A (en) * | 1984-10-24 | 1989-12-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
GB8505862D0 (en) * | 1985-03-07 | 1985-04-11 | Erba Farmitalia | Steroidic 5alpha-reductase inhibitors |
DE3607651A1 (de) * | 1986-03-06 | 1987-09-10 | Schering Ag | Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer |
US4845104A (en) * | 1986-11-20 | 1989-07-04 | Merck & Co., Inc. | Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones |
US4888336A (en) * | 1987-01-28 | 1989-12-19 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
US4910226A (en) * | 1987-04-29 | 1990-03-20 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
US4980372A (en) * | 1987-05-11 | 1990-12-25 | Ono Pharmaceutical Co., Ltd. | Benzoylaminophenoxybutanoic acid derivatives |
WO1989011282A1 (en) * | 1988-05-25 | 1989-11-30 | Smithkline Beckman Corporation | AROMATIC STEROID 5-alpha-REDUCTASE INHIBITORS |
US4970205A (en) * | 1988-12-23 | 1990-11-13 | Smithkline Beecham Corporation | Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase |
US4937237A (en) * | 1988-12-23 | 1990-06-26 | Smithkline Beckman Corporation | Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase |
US4882319A (en) * | 1988-12-23 | 1989-11-21 | Smithkline Beckman Corporation | Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase |
US5026882A (en) * | 1988-12-23 | 1991-06-25 | Smithkline Beecham Corporation | Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase |
EP0462189B1 (en) * | 1989-03-10 | 1995-09-27 | Endorecherche Inc. | Combination therapy for treatment of estrogen sensitive diseases |
EP0485392B1 (en) * | 1989-07-07 | 1998-09-09 | Endorecherche Inc. | Androgen derivatives for use in the inhibition of sex steroid activity |
WO1991000733A1 (en) * | 1989-07-07 | 1991-01-24 | Endorecherche Inc. | Method of treatment of androgen-related diseases |
US5212176A (en) * | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
JPH07505398A (ja) * | 1992-04-02 | 1995-06-15 | スミスクライン・ビーチャム・コーポレイション | 良性前立腺肥大症の治療用組成物および方法 |
-
1992
- 1992-03-16 NZ NZ241979A patent/NZ241979A/en not_active IP Right Cessation
- 1992-03-16 IL IL10124392A patent/IL101243A/en not_active IP Right Cessation
- 1992-03-19 CA CA002104793A patent/CA2104793C/en not_active Expired - Fee Related
- 1992-03-19 IE IE087992A patent/IE920879A1/en not_active IP Right Cessation
- 1992-03-19 RO RO93-01253A patent/RO113613B1/ro unknown
- 1992-03-19 HU HU9302624A patent/HUT66273A/hu unknown
- 1992-03-19 UA UA94061635A patent/UA41305C2/uk unknown
- 1992-03-19 SK SK1006-93A patent/SK284381B6/sk unknown
- 1992-03-19 JP JP4509435A patent/JPH06506227A/ja active Pending
- 1992-03-19 EP EP92910266A patent/EP0576603A1/en not_active Withdrawn
- 1992-03-19 AU AU17514/92A patent/AU666846B2/en not_active Ceased
- 1992-03-19 SG SG9603649A patent/SG80530A1/en unknown
- 1992-03-19 WO PCT/US1992/002258 patent/WO1992016213A1/en active IP Right Grant
- 1992-03-19 RU RU93055133A patent/RU2125879C1/ru not_active IP Right Cessation
- 1992-03-19 CZ CZ19931933A patent/CZ292712B6/cs not_active IP Right Cessation
-
1993
- 1993-09-17 NO NO933327A patent/NO305635B1/no unknown
- 1993-09-17 BG BG98113A patent/BG61798B1/bg unknown
-
1995
- 1995-04-25 US US08/428,595 patent/US5753641A/en not_active Expired - Lifetime
-
1998
- 1998-02-20 US US09/027,105 patent/US6046183A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2104793C (en) | 2004-06-22 |
IE920879A1 (en) | 1992-09-23 |
CZ193393A3 (en) | 1994-08-17 |
CZ292712B6 (cs) | 2003-12-17 |
NZ241979A (en) | 1996-01-26 |
RO113613B1 (ro) | 1998-09-30 |
NO933327D0 (no) | 1993-09-17 |
IL101243A0 (en) | 1992-11-15 |
CA2104793A1 (en) | 1992-09-21 |
US6046183A (en) | 2000-04-04 |
AU1751492A (en) | 1992-10-21 |
BG61798B1 (bg) | 1998-06-30 |
RU2125879C1 (ru) | 1999-02-10 |
JPH06506227A (ja) | 1994-07-14 |
US5753641A (en) | 1998-05-19 |
NO305635B1 (no) | 1999-07-05 |
HUT66273A (en) | 1994-11-28 |
SK284381B6 (sk) | 2005-02-04 |
AU666846B2 (en) | 1996-02-29 |
IL101243A (en) | 1999-12-22 |
BG98113A (bg) | 1994-06-30 |
WO1992016213A1 (en) | 1992-10-01 |
EP0576603A1 (en) | 1994-01-05 |
SG80530A1 (en) | 2001-05-22 |
SK100693A3 (en) | 1994-11-09 |
HU9302624D0 (en) | 1993-12-28 |
NO933327L (no) | 1993-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA41305C2 (uk) | Cпосіб лікування незлоякісної гіперплазії простати та фармацевтична композиція для його здійснення | |
BG102668A (en) | Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x | |
CA2148839A1 (en) | Use of alpha-1c specific compounds to treat benign prostatic hyperplasia | |
GR3033667T3 (en) | Use of non-steroidal cyclooxygenase inhibitors to treat elevated intraocular pressure | |
EP0746202A4 (en) | COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY | |
PL327735A1 (en) | Novel substituted derivatives of imidazole | |
HUP0003194A3 (en) | Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer | |
MY106484A (en) | Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia. | |
DK0706373T3 (da) | Liposomindkapslet taxol og en fremgangsmåde til anvendelse heraf | |
HK1023517A1 (en) | Formulation of 5-ht agonists. | |
MY138240A (en) | Method of treating androgenic alopecia with 5- alpha reductase inhibitors. | |
GB9304789D0 (en) | Topical composition for relieving aches and pains | |
HK1029922A1 (en) | Angiostatic agents and compositions for treating glc1a glaucoma | |
EP0646007A4 (uk) | ||
UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
TR199900556T2 (xx) | Prostat hipertrofisini ve prostat kanserini tedavi etmek i�in vas�ta. | |
EP0988054A4 (en) | METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING SYSTEMIC INFLAMMATORY REACTION SYNDROME, INCLUDING SEPTICEMIA | |
IL101574A0 (en) | Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia | |
NO944838L (no) | Arabinogalaktanderivater og anvendelser derav | |
MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
EP0369216A3 (en) | Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia | |
PL329190A1 (en) | Antagonists of alpha -adrenergic receptor | |
PL314799A1 (en) | Application of dimeticone in treating constipations | |
IL110289A0 (en) | Pharmaceutical compositions comprising 4'-iodo-4'- deoxydoxorubicin for treating amyloidosis | |
EP0906078A4 (en) | USE OF TEMPOL TO PREVENT LIGHTING AGE |